La vendita allo scoperto per HeartBeam dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di HeartBeam. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

HeartBeam (NASDAQ:BEAT) Azioni, Report sulle vendite allo scoperto

HeartBeam

HeartBeam Inc is a medical technology company primarily focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

HeartBeam Inc

News

Management

BEAT

HeartBeam Appoints Robert Eno As CEO To Lead U.S. Commercialization Efforts, While Founder Branislav Vajdic Transitions To President To Focus On Advancing Vector-Based Technology And AI Applications For Heart Health

HeartBeam Appoints Timothy Cruickshank As Chief Financial Officer, Effective Immediately

Benchmark analyst Bill Sutherland reiterates HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) with a Speculative Buy and maintains $8 price target.

Price Target

Reiteration

Analyst Ratings

Benchmark Reiterates Speculative Buy on HeartBeam, Maintains $8 Price Target

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.19) per share which missed the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 18.75 percent decrease over losses of $(0.16) per share from the same period last year.

Earnings

Earnings Misses

HeartBeam Q2 2024 GAAP EPS $(0.19) Misses $(0.17) Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.heartbeam.com%2F&amp;esheet=54089132&amp;newsitemid=20240701576961&amp;lan=en-US&amp;anchor=HeartBeam%2C+Inc.&amp;index=1&amp;md5=a8e16bb73468ac62714a82d6f6ae9bb7">HeartBeam, Inc.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced that it has been added to the Russell Microcap&#xAE; Index effective after the market close on June 28, 2024 as part of FTSE Russell's annual reconstitution.

HeartBeam Added To Russell Microcap Index

New Data Presented at Heart Rhythm Society Conference Demonstrates Continued Progress with Company's AI Program
Data Show That Applying AI to VCG Data Provides More Consistent and Reliable Detection of Atrial Flutter

Biotech

General

HeartBeam's Study Demonstrates AI Algorithm Combined with Vectorcardiography Outperforms Panel Of Cardiologists in Detecting Arrhythmias

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.15) by 13.33 percent. This is a 66 percent increase over losses of $(0.50) per share from the same period last year.

HeartBeam Q1 2024 GAAP EPS $(0.17) Misses $(0.15) Estimate

<h3>Gainers</h3>
<ul>
<li>NeuBase Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBSE#NASDAQ">NBSE</a>) stock increased by 11.1% to $0.45 during Friday's after-market session. The market value of their outstanding shares is at $1.6 million. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) shares moved upwards by 7.17% to $1.06. The company's market cap stands at $3.8 million. </li>
<li>Galera Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRTX#NASDAQ">GRTX</a>) shares moved upwards by 6.72% to $0.2. The market value of their outstanding shares is at $10.7 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) shares rose 5.85% to $0.77. The company's market cap stands at $5.2 million. </li>
<li>Asensus Surgical (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#AMEX">ASXC</a>) shares increased by 5.43% to $0.25. The company's market cap stands at $69.1 million. </li>
<li>cbdMD (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/YCBD#AMEX">YCBD</a>) stock rose 5.24% to $0.91. The market value of their outstanding shares is at $2.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Acutus Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFIB#NASDAQ">AFIB</a>) shares declined by 16.4% to $0.12 during Friday's after-market session. The company's market cap stands at $3.5 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) stock decreased by 10.36% to $1.98. The company's market cap stands at $52.1 million. </li>
<li>Mustang Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBIO#NASDAQ">MBIO</a>) shares decreased by 6.71% to $0.3. The market value of their outstanding shares is at $3.0 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares fell 5.04% to $7.35. The company's market cap stands at $6.2 million. </li>
<li>Trevena (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVN#NASDAQ">TRVN</a>) shares fell 5.0% to $0.39. The company's market cap stands at $7.1 million. </li>
<li>Monopar Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNPR#NASDAQ">MNPR</a>) stock decreased by 5.0% to $0.69. The company's market cap stands at $12.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

AFIB

ALZN

APVO

ASXC

GRTX

MBIO

MNPR

NBSE

PALI

TRVN

YCBD

12 Health Care Stocks Moving In Friday's After-Market Session

New Data Presented at the European Heart Rhythm Association Conference Marks First Scientific Presentation on HeartBeam AI, the Company's Deep Learning Technology
Data Shows HeartBeam AI Combined with VCG Greatly Improves Detection of Atrial Flutter over Single-Lead ECGs Found in Leading Smartwatches and Other Wearables

HeartBeam Presents Results On AI Capabilities For Detecting Arrhythmias

Shares of FedEx Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fdx#NYSE">FDX</a>) rose sharply in today&rsquo;s pre-market trading after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion <a href="https://www.benzinga.com/news/earnings/24/03/37881578/fedex-stock-climbs-on-q3-results-eps-beat-5b-share-buyback">share repurchase program</a>.
FedEx reported quarterly earnings of $3.86 per share which beat the analyst consensus estimate of $3.45 by 11.88% and represents a 13.2% increase over earnings of $3.41 per share from the same period last year. Quarterly sales came in at $21.7 billion, missing the analyst consensus estimate of $22.04 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
FedEx shares surged 12.4% to $297.72 in pre-market trading
Here are some other stocks moving in pre-market trading.
<h3>Gainers</h3>
<ul>
<li>Murano Global Investments PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mrno#NASDAQ">MRNO</a>) shares rose 266.4% to $35.43 in pre-market trading after falling 46% on Thursday.</li>
<li>Nova LifeStyle, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nvfy#NASDAQ">NVFY</a>) rose 62.5% to $2.99 in pre-market trading after gaining around 22% on Thursday.</li>
<li>BIOLASE, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/biol#NASDAQ">BIOL</a>) shares rose 32.8% to $0.1990 in pre-market trading after the company reported better-than-expected fourth-quarter earnings results.</li>
<li>Griid Infrastructure Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/grdi#NASDAQ">GRDI</a>) climbed 30.9% to $1.44 in pre-market trading.</li>
<li>Visionary Holdings Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gv#NASDAQ">GV</a>) shares gained 16.1% to $0.1950 in pre-market trading after dipping 6% on Thursday.</li>
<li>SU Group Holdings Limited (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/sugp#NASDAQ">SUGP</a>) gained 13.1% to $3.29 in pre-market trading after declining around 9% on Thursday.</li>
<li>HeartBeam, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/beat#NASDAQ">BEAT</a>) shares rose 10.8% to $2.56 in pre-market trading as the company reported fourth-quarter financial results.</li>
<li>Ocugen, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ocgn#NASDAQ">OCGN</a>) gained 9% to $1.46 in pre-market trading after gaining 8% on Thursday. Ocugen recently appointed Huma Qamar, MD, MPH as Chief Medical Officer.</li>
<li>Worthington Steel, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/ws#NYSE">WS</a>) gained 3.9% to $33.15 in pre-market trading as the company posted stronger-than-expected results for its third quarter on Thursday.</li>
</ul>
<h3>Losers</h3>
<ul>
<li>Abits Group Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/abts#NASDAQ">ABTS</a>) dipped 17.6% to $0.6398 in pre-market trading after declining over 6% on Thursday.</li>
<li>Lululemon Athletica Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/lulu#NASDAQ">LULU</a>) declined 12.8% to $417.25 in pre-market trading. Lululemon posted better-than-expected results for its fourth quarter, but issued a weak forecast for the first quarter.</li>
<li>Selina Hospitality PLC (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/slna#NASDAQ">SLNA</a>) fell 11.5% to $0.2478 pre-market trading after jumping around 30% on Thursday.</li>
<li>Pyxis Oncology, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/pyxs#NASDAQ">PYXS</a>) fell 11.3% to $4.40 in pre-market trading after falling over 8% on Thursday. The company, on Thursday, reported FY23 financial results.</li>
<li>Ispire Technology Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ispr#NASDAQ">ISPR</a>) fell 11.3% to $7.20 pre-market trading after dipping 15% on Thursday.</li>
<li>Asset Entities Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/asst#NASDAQ">ASST</a>) fell 10.9% to $0.5750 in pre-market trading. Asset Entities shares surged around 23% on Thursday after the company announced that it entered into an agreement with Zendrop.</li>
<li>MMTec, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/mtc#NASDAQ">MTC</a>) shares tumbled 10.7% to $2.05 in pre-market trading after gaining 20% on Thursday.</li>
<li>JOANN Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/joan#NASDAQ">JOAN</a>) shares fell 9.1% to $0.14 in pre-market trading after surging 14% on Thursday.</li>
<li>Next.e.GO N.V. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/egox#NASDAQ">EGOX</a>) shares fell 8.4% to $0.0461 in pre-market trading after dipping 16% on Thursday.</li>
<li>NIKE, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/nke#NYSE">NKE</a>) shares tumbled 6.3% to $94.49. Nike reported upbeat earnings and sales results for its third quarter on Thursday.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/03/37885620/fedex-nike-and-3-stocks-to-watch-heading-into-friday"> FedEx, Nike And 3 Stocks To Watch Heading Into Friday</a>

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Trading Ideas

ABTS

ASST

BIOL

EGOX

GRDI

ISPR

JOAN

LULU

MRNO

NVFY

OCGN

PYXS

SLNA

SUGP

Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported its Q4 earnings results on Wednesday, March 20, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
HeartBeam missed estimated earnings by 0.0%, reporting an EPS of $-0.13 versus an estimate of $-0.13.
Revenue was down $0 from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.0 which was followed by a 10.0% drop in the share price the next day.

To track all earnings releases for HeartBeam <a href="https://www.benzinga.com/quote/BEAT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: HeartBeam Q4 Earnings

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) reported quarterly losses of $(0.13) per share which met the analyst consensus estimate.

HeartBeam Q4 2023 GAAP EPS $(0.13), Inline

<h3>Companies Reporting Before The Bell</h3>
&bull; UP Fintech Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIGR#NASDAQ">TIGR</a>) is expected to report quarterly earnings at $0.07 per share on revenue of $207.00 million.
&bull; Fanhua (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FANH#NASDAQ">FANH</a>) is estimated to report earnings for its fourth quarter.
&bull; Mogo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOGO#NASDAQ">MOGO</a>) is likely to report quarterly loss at $0.09 per share on revenue of $12.14 million.
&bull; Ollie&#39;s Bargain Outlet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OLLI#NASDAQ">OLLI</a>) is projected to report quarterly earnings at $1.15 per share on revenue of $641.29 million.
&bull; Sportradar Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SRAD#NASDAQ">SRAD</a>) is estimated to report quarterly earnings at $0.04 per share on revenue of $271.46 million.
&bull; Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) is estimated to report quarterly earnings at $1.49 per share on revenue of $956.43 million.
&bull; BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) is projected to report quarterly earnings at $2.64 per share on revenue of $1.99 billion.
&bull; Kingsoft Cloud Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KC#NASDAQ">KC</a>) is likely to report quarterly loss at $0.16 per share on revenue of $242.39 million.
&bull; PDD Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDD#NASDAQ">PDD</a>) is projected to report quarterly earnings at $1.60 per share on revenue of $11.01 billion.
&bull; H World Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTHT#NASDAQ">HTHT</a>) is likely to report quarterly earnings at $0.36 per share on revenue of $756.94 million.
&bull; So-Young Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SY#NASDAQ">SY</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $51.04 million.
&bull; JinkoSolar Holding Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JKS#NYSE">JKS</a>) is estimated to report quarterly earnings at $2.50 per share on revenue of $4.28 billion.
&bull; Huize Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HUIZ#NASDAQ">HUIZ</a>) is expected to report earnings for its fourth quarter.
&bull; J.Jill (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JILL#NYSE">JILL</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $147.40 million.
&bull; Bakkt Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKKT#NYSE">BKKT</a>) is expected to report quarterly loss at $0.13 per share on revenue of $15.25 million.
&bull; General Mills (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>) is projected to report quarterly earnings at $1.04 per share on revenue of $4.96 billion.
&bull; Signet Jewelers (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SIG#NYSE">SIG</a>) is estimated to report quarterly earnings at $6.35 per share on revenue of $2.54 billion.
<h3>Companies Reporting After The Bell</h3>
&bull; Vasta Platform (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSTA#NASDAQ">VSTA</a>) is estimated to report quarterly earnings at $0.17 per share on revenue of $109.49 million.
&bull; Nortech Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSYS#NASDAQ">NSYS</a>) is estimated to report earnings for its fourth quarter.
&bull; Sadot Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDOT#NASDAQ">SDOT</a>) is estimated to report quarterly earnings at $0.00 per share on revenue of $186.43 million.
&bull; FGI Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGI#NASDAQ">FGI</a>) is estimated to report quarterly earnings at $0.07 per share on revenue of $30.40 million.
&bull; Guess (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>) is projected to report quarterly earnings at $1.56 per share on revenue of $855.54 million.
&bull; Avinger (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) is likely to report earnings for its fourth quarter.
&bull; Micron Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) is likely to report quarterly loss at $0.26 per share on revenue of $5.33 billion.
&bull; Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) is likely to report earnings for its fourth quarter.
&bull; 17 Education &amp; Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YQ#NASDAQ">YQ</a>) is projected to report earnings for its fourth quarter.
&bull; Avino Silver &amp; Gold Mines (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/ASM#AMEX">ASM</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $19.60 million.
&bull; Corporacion America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CAAP#NYSE">CAAP</a>) is projected to report quarterly earnings at $0.29 per share on revenue of $431.10 million.
&bull; Hall Of Fame Resort (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOFV#NASDAQ">HOFV</a>) is projected to report quarterly loss at $2.60 per share on revenue of $5.48 million.
&bull; Trevi Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRVI#NASDAQ">TRVI</a>) is estimated to report earnings for its fourth quarter.
&bull; Worthington Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WOR#NYSE">WOR</a>) is estimated to report quarterly earnings at $0.75 per share on revenue of $326.97 million.
&bull; Lithium Americas (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAAC#NYSE">LAAC</a>) is likely to report quarterly earnings at $0.04 per share on revenue of $18.10 million.
&bull; CuriosityStream (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CURI#NASDAQ">CURI</a>) is expected to report quarterly loss at $0.15 per share on revenue of $15.80 million.
&bull; LexinFintech Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LX#NASDAQ">LX</a>) is likely to report earnings for its fourth quarter.
&bull; Five Below (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVE#NASDAQ">FIVE</a>) is expected to report quarterly earnings at $3.78 per share on revenue of $1.35 billion.
&bull; KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) is expected to report quarterly earnings at $1.57 per share on revenue of $1.46 billion.
&bull; Chewy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHWY#NYSE">CHWY</a>) is expected to report quarterly loss at $0.04 per share on revenue of $2.77 billion.
&bull; Enerpac Tool Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPAC#NYSE">EPAC</a>) is projected to report quarterly earnings at $0.36 per share on revenue of $141.10 million.
&bull; HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) is likely to report quarterly loss at $0.13 per share on revenue of $40 thousand.
&bull; AuthID (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AUID#NASDAQ">AUID</a>) is likely to report earnings for its fourth quarter.
&bull; Sera Prognostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SERA#NASDAQ">SERA</a>) is projected to report quarterly loss at $0.26 per share on revenue of $50 thousand.
&bull; Steelcase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCS#NYSE">SCS</a>) is estimated to report quarterly earnings at $0.21 per share on revenue of $780.25 million.
&bull; OmniAb (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OABI#NASDAQ">OABI</a>) is projected to report quarterly loss at $0.15 per share on revenue of $7.47 million.
&bull; Alvotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALVO#NASDAQ">ALVO</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $68.00 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

ALVO

AUID

AVGR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BNTX

CAAP

CHWY

CURI

EPAC

FANH

FIVE

HOFV

HTHT

HUIZ

JILL

LAAC

MOGO

NSYS

OABI

OLLI

Citigourp Global Markets 2% Protected Notes Linked To The Djia

RANI

SDOT

SERA

SRAD

TIGR

TRVI

VSTA

Earnings Scheduled For March 20, 2024

HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-20. Here's what investors need to know before the announcement.
Analysts estimate that HeartBeam will report an earnings per share (EPS) of $-0.13. 
HeartBeam bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company missed EPS by $0.00, which was followed by a 9.63% drop in the share price the next day.
Here's a look at HeartBeam's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.13</td>
<td>-0.23</td>
<td>-0.31</td>
<td>-0.37</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.13</td>
<td>-0.16</td>
<td>-0.50</td>
<td>-0.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-10.0%</td>
<td>-2.0%</td>
<td>-5.0%</td>
<td>-17.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1710860525_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of HeartBeam were trading at $2.32 as of March 18. Over the last 52-week period, shares are down 7.6%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/BEAT/earnings">To track all earnings releases for HeartBeam visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

A Preview Of HeartBeam's Earnings

HeartBeam Announces First Patients Enrolled In Study Evaluating AIMIGo System For Synthesizing A 12-Lead ECG

Heartbeam Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) shares are trading higher by 3.5% to $2.35 Tuesday, pulling back following the session high of $2.70. The earlier move higher came despite a lack of company-specific news for the session. 
The company last week said it secured two new patents from the United States Patent and Trademark Office for its vectorelectrocardiography (VECG) technology, bringing its total to 14 issued US patents and 4 international patents. 
The VECG technology collects 3D signals of the heart and converts them into a 12-lead ECG. These patents reinforce HeartBeam&#8217;s commitment to transforming cardiac care by enabling personalized insights through portable, patient-friendly devices such as credit-card sized systems, extended wear patches or watches. 
The first patent focuses on a mobile three-lead cardiac monitoring device and method for automated diagnostics, aiding in the detection of heart attacks. The second patent covers HeartBeam&#8217;s wrist-based ECG system, which combines continuous monitoring with the ability to take a high sensitivity 12-lead ECG.
See Also: <a href="https://www.benzinga.com/markets/equities/24/03/37615483/inflation-rises-more-than-expected-to-3-2-rebuffs-expectations-of-june-fed-rate-cut">Inflation Rises More Than Expected To 3.2% In February, Rebuffs Expectations Of June Fed Rate Cut</a>
<h2 class="wp-block-heading">Is BEAT A Good Stock To Buy?</h2>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages &#8211; like <a href="https://www.benzinga.com/quote/BEAT">HeartBeam</a>&#8216;s page for example &#8211; there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) does not pay a dividend, but obviously has a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company that is due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. Looking through the latest news on <a href="https://www.benzinga.com/quote/BEAT">HeartBeam</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, BEAT has a 52-week high of $3.74 and a 52-week low of $1.06.

What's Going On With Heartbeam (BEAT) Stock?

<h3>Gainers</h3>
<ul>
<li>Psyence Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PBM#NASDAQ">PBM</a>) stock moved upwards by 35.3% to $1.38 during Thursday's regular session. The market value of their outstanding shares is at $18.4 million. </li>
<li>ZyVersa Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZVSA#NASDAQ">ZVSA</a>) stock increased by 28.74% to $0.99. The company's market cap stands at $4.5 million. </li>
<li>Creative Medical Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELZ#NASDAQ">CELZ</a>) stock increased by 28.18% to $6.1. The market value of their outstanding shares is at $8.4 million. </li>
<li>HeartBeam (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BEAT#NASDAQ">BEAT</a>) stock rose 26.53% to $2.05. The company's market cap stands at $53.9 million. </li>
<li>Ocean Biomedical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCEA#NASDAQ">OCEA</a>) shares increased by 24.4% to $5.03. The market value of their outstanding shares is at $171.3 million. </li>
<li>Quantum-Si (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QSI#NASDAQ">QSI</a>) shares rose 22.36% to $1.97. The market value of their outstanding shares is at $279.2 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Avid Bioservices (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDMO#NASDAQ">CDMO</a>) stock fell 31.2% to $6.04 during Thursday's regular session. The market value of their outstanding shares is at $382.2 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) stock fell 31.2% to $6.53. The company's market cap stands at $33.8 million. </li>
<li>Nexalin Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXL#NASDAQ">NXL</a>) shares fell 27.93% to $0.37. The market value of their outstanding shares is at $2.7 million. </li>
<li>BeyondSpring (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BYSI#NASDAQ">BYSI</a>) stock declined by 20.18% to $2.73. The company's market cap stands at $106.5 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) stock decreased by 19.54% to $12.4. The market value of their outstanding shares is at $388.6 million. The company's, Q4 earnings came out yesterday. </li>
<li>Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>) shares declined by 19.46% to $73.44. The company's market cap stands at $7.9 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BYSI

CDMO

CELZ

OCEA

PEPG

VKTX

ZVSA

12 Health Care Stocks Moving In Thursday's Intraday Session

HeartBeam Receives Two New US Patents For Its Core Cardiac Monitoring Technology

Jaguar Health, Altamira Therapeutics,Erasca among healthcare movers

Jaguar Health, Altamira Therapeutics, Erasca among healthcare movers

HeartBeam added to Russell Microcap Index

HeartBeam GAAP EPS of -$0.19 misses by $0.02

HeartBeam, Inc. (BEAT) Q2 2024 Earnings Call Transcript

HeartBeam, Inc. 2024 Q2 - Results - Earnings Call Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
HeartBeam (NASDAQ:<a href="https://investorplace.com/stock-quotes/beat-stock-quote/">BEAT</a>) just reported results for the second quarter of 2024.<ul><li>HeartBeam reported earnings per share of -19 cents. This was below the analyst estimate for EPS of -16 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/beat-stock-earnings-heartbeam-for-q2-of-2024/">BEAT Stock Earnings: HeartBeam Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BEAT Stock Earnings: HeartBeam Misses EPS for Q2 2024

HeartBeam names Cruickshank as finance chief

The latest announcement is out from HeartBeam ( ($BEAT) ). HeartBeam, Inc. has strengthened its executive team by appointing Timothy Cruickshank as...

HeartBeam Appoints New CFO to Bolster Financial Strategy

HeartBeam appoints Robert Eno as CEO

AKAN

BEATW

CYTO

ERAS

GNLX

JAGX

PTIX

SILO

Press Releases

Epitel Announces Appointment of Wearables Industry Leader Ken Nelson to Board of Directors

HeartBeam Added to Russell Microcap® Index

HeartBeam to Host Second Quarter 2024 Results Conference Call on Wednesday, August 14, 2024 at 4:30 p.m. Eastern Time

HeartBeam Reports Second Quarter 2024 Results

HeartBeam Names Timothy Cruickshank as Chief Financial Officer

HeartBeam Appoints Dr. Lance Myers as Chief AI Scientist

HeartBeam Appoints Robert Eno as Chief Executive Officer in Preparation for US Commercialization

Lifesaving Portable, AI Augmented Cardiac Monitoring Technology Poised for Commercial Launch Under New Industry Leader CEO: Heartbeam, Inc. (NASDAQ: BEAT)

HeartBeam Named "Rising Star" at the 6th Annual Digital Health Hub Foundation Awards

HeartBeam to Host Third Quarter 2024 Results Conference Call on Thursday, November 7, 2024 at 4:30 p.m. Eastern Time

Adagio Medical Holdings, Inc - Common Stock

Adagio Medical Holdings

Apyx Medical

Accelerate Diagnostics, Inc. - Common Stock

Accelerate Diagnostics

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

Envoy Medical, Inc. - Class A Common Stock

Envoy Medical

Co-Diagnostics

CytoSorbents

DIH Holding US, Inc. - Class A Common Stock

DIH Holding US

Daxor

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Comments

HeartBeam

Vendite allo scoperto

HeartBeam (NASDAQ:BEAT) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO